Nurix Therapeutics (NRIX)

• Market cap: $1.85B
• 1 day: -3.34%
• 5 days: -7.23%
• 1 month: 42.38%
• 3 months: 112.49%
• 6 months: 59.88%
• Year to date: -6.66%
• 1 year: -14.02%
• 5 years: -58.53%
• 10 years: -4.21%
• Sector: Healthcare
• Industry: Biotechnology

About: Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

Employees: 286